This is the authors' abstract. We don't add key points for this paper.
This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rovaris et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: